Table 4.
HR-HPV incident infections from enrollment to 24 months follow up, by study arm
| HR-HPV genotype | Intervention | Control | IRR (95%CI) | ||
|---|---|---|---|---|---|
| Incident/N* | % | Incident/N* | % | Intervention vs control | |
| 16 | 4/69 | 5.8 | 11/74 | 14.9 | 0.39 (0.12–1.22) |
| 18 | 3/70 | 4.3 | 9/81 | 11.1 | 0.39 (0.10–1.42) |
| 31 | 4/73 | 5.5 | 5/86 | 5.8 | 0.94 (0.25–3.51) |
| 33 | 2/69 | 2.9 | 7/80 | 8.8 | 0.33 (0.07–1.59) |
| 35 | 4/66 | 6.1 | 5/80 | 6.3 | 0.97 (0.26–3.61) |
| 39 | 1/73 | 1.4 | 5/86 | 5.8 | 0.24 (0.03–2.02) |
| 45 | 3/73 | 4.1 | 8/78 | 10.3 | 0.40 (0.11–1.51) |
| 51 | 5/68 | 7.4 | 10/72 | 13.9 | 0.53 (0.18–1.55) |
| 52 | 7/69 | 10.1 | 7/85 | 8.2 | 1.23 (0.43–3.51) |
| 56 | 2/76 | 2.6 | 5/84 | 6.0 | 0.44 (0.09–2.28) |
| 58 | 2/66 | 3.0 | 10/77 | 13.0 | 0.23 (0.05–1.06) |
| 59 | 1/69 | 1.4 | 5/78 | 6.4 | 0.23 (0.03–1.94) |
| 66 | 2/76 | 2.6 | 5/81 | 6.2 | 0.43 (0.08–2.20) |
| 68 | 6/70 | 8.6 | 8/78 | 10.3 | 0.84 (0.29–2.41) |
*
The denominators are samples which had amplifiable cellular or viral DNA at both enrollment and follow up, and were negative for the specific genotype at enrollment.